ArticleAmerican journal of translational research2021
Anti-hypoxia effects of walnut oligopeptides (
Article in American journal of translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 5 citations in OpenAlex.
- Antioxidant Peptides Derived from Woody Oil Resources: Mechanisms of Redox Protection and Emerging Therapeutic Opportunities.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Walnut Oligopeptide Delayed Improved Aging-Related Learning and Memory Impairment in SAMP8 Mice.Nutrients · 2022Article
- Nicotinic acid supplementation contributes to the amelioration of Alzheimer's disease in mouse models.Annals of translational medicine · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the anti-hypoxia effects of walnut oligopeptides (WOPs) in mice.
methodsRandomly divide the mice into 4 experimental sets. Then randomly divide each set of mice into 5 groups, including one vehicle control group, one whey protein group (220 mg/kg), and three WOPs intervention groups (110 mg/kg, 220 mg/kg, 440 mg/kg). Test substances were administered orally to mice via the drinking water for 30 days.
resultsWOPs significantly extended the normobaric hypoxia survival time, sodium nitrite toxicosis survival time, and acute cerebral ischemia survival time. Notably, WOPs increased red blood cell (RBC), hemoglobin (Hb) and hematocrit (Hct) levels, decreased malonaldehyde (MDA) content and lactate content in brain, enhanced brain lactate dehydrogenase (LDH) activity, and promoted the expression levels of hypoxia-inducible factor 1alpha (HIF1α) mRNA and vascular endothelial growth factor (VEGF) mRNA.
conclusionWOPs have anti-hypoxia effects, and the mechanism may involve the following aspects: the first is to improve the blood's oxygen carrying capacity and oxygen utilization rate, the second is to minimize the lesion of lipid peroxidation, the third is to increase the brain's ability to buffer against lactic acidosis of mice, and the fourth is to promote angiogenesis and regulate hypoxia response.
Indexed as
Identifiers
34150038PMC8205819W3174326424What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.